Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.

This article aims to improve oncology nurses' knowledge about the benefits and risks of midostaurin therapy and to provide guidance on the identification and management of eligible patients. METHODS: The clinical data that supported the U.S. Food and Drug Administration's approval of midostaurin are reviewed, and supporting safety and management considerations are provided based on the authors' experiences as nurses and advanced practice providers caring for patients who received midostaurin during these key clinical trials. FINDINGS: Nausea and vomiting are the most frequent nonhematologic adverse events reported with midostaurin; therefore, administer midostaurin with antiemetics, and recommend taking it with food. Care should be taken when midostaurin is coadministered with strong CYP3A4 inhibitors. PMID: 31730602 [PubMed - in process]
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research